Compare Enveric Biosciences Inc (ENVB) vs Altria Group Inc (MO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Altria Group Inc — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Altria Group Inc trades at $71.23 (market cap $115.85B). The key difference: Altria Group Inc is far larger — about 17316.9× Enveric Biosciences Inc's market cap, and Altria Group Inc pays a 6.4% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Altria Group Inc for 154 Days on average.
| ENVB | MO | |
|---|---|---|
Market Cap | $6.69M | $115.85B |
Volume | 41,141 | 6,934,962 |
Sector | Health | Consumer Staples |
52-Week High | $10.80 | $74.92 |
52-Week Low | $1.27 | $54.72 |
Typical Hold Time | 14 Days | 154 Days |
Enterprise Value | -$1.60M | $138.06B |
Dividend Yield | — | 6.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
Altria Group (MO) trades at $69.39, up 1.22% today, with a bullish technical signal from moving averages. The stock shows strong profitability with a 39% net income margin and a 6.6% dividend yield, though recent earnings have been mixed with two misses in the last four quarters. Cash flow improved in 2025 with net cash flow of $1.33 billion, but the balance sheet carries negative equity of -$2.24 billion due to high liabilities.
The outlook is balanced: analyst consensus is bullish with a $69.71 price target, but risks include regulatory pressures on tobacco, declining margins, and high debt. The dividend appears sustainable from cash flow, yet negative equity and business shrinkage pose long-term concerns for income-focused investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →
